Use of animal models in IPF research

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Translational Research

Background:

• Idiopathic pulmonary fibrosis (IPF) is a severe lung disease with limited effective treatments.
• Pirfenidone and nintedanib are the only approved drugs, highlighting the need for better therapeutic options.
• Current preclinical models for IPF require significant improvement to accurately reflect human disease progression and treatment response.

Purpose of the Study:

• Critically evaluate the current state of preclinical models for IPF.
• Identify challenges and propose improvements for IPF preclinical research.
• Enhance the predictive value of preclinical models for clinical drug efficacy in IPF.

Main Methods:

• Review and critical analysis of existing IPF preclinical models.
• Discussion of adaptations to the bleomycin-induced lung fibrosis model.
• Evaluation of current drug dosing strategies (prophylactic vs. therapeutic) in preclinical IPF studies.
• Assessment of commonly used endpoints in preclinical IPF research versus clinical practice.

Main Results:

• The bleomycin-induced lung fibrosis model can be modified for more progressive fibrosis, mimicking human IPF.
• Prophylactic drug dosing in models does not reflect clinical treatment of established fibrosis.
• Histological scoring and collagen content are common preclinical endpoints, differing from clinical imaging and lung function tests.

Conclusions:

• Adapting the bleomycin model with a focus on progressive fibrosis is recommended.
• Therapeutic dosing regimens in preclinical models are essential for evaluating drugs for established IPF.
• Incorporating clinically relevant endpoints like imaging and lung function tests in preclinical studies will improve translational validity for IPF drug development.